Skip to content
Disclosery

13F-HR filed by Atle Fund Management AB

Atle Fund Management AB filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-12, with 36 holding rows worth $212,751,021.

Accession
0001381843-24-000008
Filer
CIK 1381843
Filed
2024-11-12
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2024

A holdings report, 36 entries on the cover page, a total value of $212,751,021 stated on the cover page (in dollars after the unit check, H1), rows summing to $212,751,021 with VALUE read as dollars as filed, 13F file number 028-12171. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Eli Lilly and Company532457108COM30,564$27,077,870dollars as filed
UnitedHealth Group Inc91324P102COM35,490$20,750,293dollars as filed
Merck & Co.,Inc.58933Y105COM154,699$17,567,618dollars as filed
Thermo Fisher Scientific Inc.883556102COM22,012$13,615,963dollars as filed
Amgen Inc.031162100COM28,965$9,332,813dollars as filed
Boston Scientific Corporation101137107COM106,172$8,897,214dollars as filed
AbbVie,Inc.00287Y109COM44,486$8,785,095dollars as filed
Stryker Corporation863667101COM23,460$8,475,160dollars as filed
CENCORA INC COM03073E105Stock36,544$8,225,324dollars as filed
Vertex Pharmaceuticals Incorporated92532F100COM16,993$7,903,104dollars as filed
REGENERON PHARMACEUTICALS COM75886F107Stock7,028$7,388,115dollars as filed
NEUROCRINE BIOSCIENCES INC64125C109COM60,607$6,983,139dollars as filed
ALKERMES PLCG01767105SHS236,610$6,622,714dollars as filed
INTRA-CELLULAR THERAPIES INC46116X101COMMON STOCK84,578$6,188,572dollars as filed
HARMONY BIOSCIENCES HLDGS IN413197104COM151,875$6,075,000dollars as filed
UFP TECHNOLOGIES INC902673102COM18,048$5,715,802dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM138,321$5,394,519dollars as filed
DEXCOM INC COM252131107Stock53,757$3,603,869dollars as filed
ARCELLX INC COMMON STOCK03940C100Stock40,230$3,359,607dollars as filed
IONIS PHARMACEUTICALS INC COM462222100Stock82,691$3,312,601dollars as filed
CARDINAL HEALTH INC14149Y108COM27,500$3,039,300dollars as filed
AMICUS THERAPEUTICS INC03152W109COM275,472$2,942,041dollars as filed
MERUS N VN5749R100COM50,687$2,532,323dollars as filed
EDWARDS LIFESCIENCES CORP COM28176E108Stock36,505$2,408,965dollars as filed
NEWAMSTERDAM PHARMA CO NVN62509109COMMON STOCK138,983$2,307,118dollars as filed
SUMMIT THERAPEUTICS INC86627T108COM86,013$1,883,685dollars as filed
IMMUNOCORE HLDGS PLC ADS45258D105ADR54,060$1,682,888dollars as filed
KRYSTAL BIOTECH INC COM501147102Stock9,202$1,675,040dollars as filed
AUTOLUS THERAPEUTICS PLC SPON05280R100COM442,423$1,605,995dollars as filed
CORBUS PHARMACEUTICALS21833P301COM NEW69,573$1,435,291dollars as filed
BRIDGEBIO PHARMA INC10806X102COM53,432$1,360,379dollars as filed
SOLENO THERAPEUTICS INC834203309COM26,390$1,332,431dollars as filed
Mersana Therapeutics Inc59045L106Common Stock538,621$1,017,994dollars as filed
MEREO BIOPHARMA GROUP PLC589492107CMN200,000$822,000dollars as filed
CABALETTA BIO INC12674W109COMMON STOCK168,522$795,424dollars as filed
PHARVARIS NVN69605108COMMON STOCK34,328$635,755dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001381843-24-000008this filing2024-11-12acceptance time not in the bulk data set